IMEIK(SZ:300896) Bei Ke Cai Jing·2025-07-23 06:20Core Viewpoint - The dispute between Aimeike and Jiangsu Wuzhong regarding the exclusive agency rights for AestheFill has escalated, with Aimeike asserting legal grounds for terminating the agreement due to alleged violations by Jiangsu Wuzhong and its affiliates [1][3][4]. Group 1: Company Actions and Responses - Aimeike claims that Jiangsu Wuzhong's subsidiary, Datou Medical, has transferred its exclusive distribution rights to its controlling shareholder, Wu Zhongmei, which violates the exclusive distribution agreement [1][3]. - Aimeike emphasizes that the termination of the agreement with Datou Medical is legally justified and will rely on judicial rulings for any disputes [1]. - Aimeike refutes allegations of supply delays, stating that the last shipment to Datou Medical occurred in mid-July and that supply to the Chinese market has slightly increased compared to the same period last year [1][2]. Group 2: Jiangsu Wuzhong's Position - Jiangsu Wuzhong disputes Aimeike's claims, asserting that Datou Medical has not transferred agency rights and that the exclusive agency agreement does not allow for termination based on administrative penalties against related parties [4]. - Jiangsu Wuzhong accuses Aimeike of intentionally delaying shipments to Datou Medical, which has led to product shortages and harmed consumer rights [4]. - Jiangsu Wuzhong's official statement claims that Aimeike is abusing its market position to disrupt the supply chain, which contradicts the spirit of the contract [4]. Group 3: Market Reactions - Following the announcement of the dispute, Jiangsu Wuzhong's stock price fell to 1.62 yuan per share, a decline of 4.71%, with a market capitalization of 1.154 billion yuan [6]. - In contrast, Aimeike's stock rose to 186.83 yuan per share, an increase of 0.99%, with a market capitalization of 56.533 billion yuan [6].